PSG Enhances Artemetrx GeneCQ™ with Expanded Pipeline Intelligence to Help Healthcare Payers Navigate Growing Gene Therapy Market
Posted on June 12, 2025
Enhanced Platform Helps Payers Proactively Manage Gene Therapy Costs While Ensuring Patient Access
DALLAS, TX – June 12, 2025 – Pharmaceutical Strategies Group (“PSG“), an EPIC company, announces significant enhancements to its proprietary Artemetrx GeneCQ™ solution, designed to predict the risk of gene therapy exposure so healthcare payers can effectively manage financial exposure in a dynamic market.
These latest updates incorporate expanded disease state modeling and enhanced predictive analytics to address the accelerating pace of FDA approvals for novel gene therapies. With US spending on cell, gene, and RNA-based therapies expected to more than double in the next four years, healthcare payers face unprecedented challenges in balancing access to life-saving treatments with sustainable cost management.
“The gene therapy landscape is evolving at a rapid speed, and our clients need solutions that can keep pace with this innovation,” stated Rebekah Gregg, Chief Operating Officer of PSG. “These GeneCQ enhancements represent our commitment to providing healthcare payers with the most comprehensive and forward-looking tools available to navigate this complex environment while ensuring patients receive the transformative care they need.”
PSG has expanded Artemetrx GeneCQ by adding predictive models for new and upcoming therapies for several rare indications. These updates enable more precise risk identification and financial forecasting across a broader spectrum of high-cost therapeutic areas.
| Therapy Name | Indication | Company | FDA Status |
|---|---|---|---|
| Kresladi | Leukocyte Adhesion Deficiency | Rocket Pharmaceuticals | Pipeline |
| Kebilidi | Aromatic L-amino acid decarboxylase Deficiency | PTC Therapeutics | Pipeline |
| Mozafancogene Autotemcel | Fanconi Anemia | Rocket Pharmaceuticals | Pipeline |
| Lumevoq | Leber Hereditary Optic Neuropathy | GenSight Biologics | Pipeline |
| Zevaskyn (prademagene zamikeracil) | Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Abeona Therapeutics Inc | Approved |
| Sonpiretigene Isteparvovec (MCO-010) | Retinitis Pigmentosa | Nanoscope Therapeutics | Pipeline |
| UX-111 | Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome A) | Ultragenyx Pharmaceutical | Pipeline |
“We’re seeing exciting client uptake as healthcare payers recognize the critical need for proactive gene therapy management,” said Travis Baughn, VP of Artemetrx Business Development at PSG. “This enthusiasm has driven our continued investment in these enhancements, delivering greater value by helping payers balance fiscal responsibility with optimal member outcomes.”
Learn more about the enhanced Artemetrx GeneCQ and request a demo here.
About Pharmaceutical Strategies Group (PSG)
Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG is an independent consultant, empowering healthcare payers to manage their pharmacy program better. As a strategic partner, PSG helps clients by providing industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. www.psgconsults.com.
About Artemetrx®
Artemetrx is a proprietary SaaS platform developed by Pharmaceutical Strategies Group, an EPIC company. As a revolutionary technology solution integrating pharmacy and medical claims data for specialty drug cost management, Artemetrx provides market-leading specialty drug insights to payers. It delivers unparalleled intelligence and line-of-sight into serious challenges perpetuating out-of-control drug costs and compromised patient outcomes. PSG’s innovative drug management solutions, including Artemetrx, deliver actionable insights with exceptional financial and clinical value. PSG is a strategic partner through industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. https://www.psgconsults.com/solutions/data-analytics
Media Contact